• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

帕金森病患者血浆中结合型、游离型和总左旋多巴的测量。

Bound, free, and total L-dopa measurement in plasma of Parkinson's disease patients.

机构信息

Department of Neurology, St. Joseph Hospital Berlin-Weißensee, Gartenstr. 1, 13088, Berlin, Germany.

Thanares GmbH, Hermannswerder 14, 14473, Potsdam, Germany.

出版信息

J Neural Transm (Vienna). 2019 Nov;126(11):1417-1420. doi: 10.1007/s00702-019-02057-1. Epub 2019 Aug 8.

DOI:10.1007/s00702-019-02057-1
PMID:31396704
Abstract

Peaks and troughs of levodopa in plasma contribute to pulsatile postsynaptic dopamine receptor stimulation in patients with Parkinson's disease. Measurement of levodopa plasma levels mostly only considers the total levodopa plasma concentration. Objectives were to determine bound, free, and total plasma levodopa and to investigate their correlations to each other. We employed reversed-phase high-performance liquid chromatography combined with electrochemical detection. Bound levodopa was computed as difference between total and free L-dopa values. Close correlations between free and total (R = 0.93, p < 0.0001), bound and total (R = 0.91, p < 0.0001) plasma levodopa appeared. A considerable variability of levodopa concentrations occurred. The ratio between bound and free levodopa did not differ in patients with a higher and lower oral daily levodopa dosing. Free, bound, and total levodopa plasma levels are closely related. Estimation of the total levodopa level only seems to be meaningful.

摘要

血浆中左旋多巴的峰谷变化导致帕金森病患者突触后多巴胺受体的脉冲式刺激。左旋多巴血浆水平的测量大多只考虑总左旋多巴血浆浓度。目的是确定结合型、游离型和总血浆左旋多巴,并研究它们之间的相关性。我们采用反相高效液相色谱法结合电化学检测。结合型左旋多巴通过总左旋多巴值减去游离左旋多巴值计算得出。游离和总(R = 0.93,p < 0.0001)、结合和总(R = 0.91,p < 0.0001)的血浆左旋多巴之间存在密切的相关性。左旋多巴浓度的变异性很大。每日口服左旋多巴剂量较高和较低的患者之间,结合型和游离型左旋多巴的比值没有差异。游离型、结合型和总血浆左旋多巴水平密切相关。仅估计总左旋多巴水平似乎才有意义。

相似文献

1
Bound, free, and total L-dopa measurement in plasma of Parkinson's disease patients.帕金森病患者血浆中结合型、游离型和总左旋多巴的测量。
J Neural Transm (Vienna). 2019 Nov;126(11):1417-1420. doi: 10.1007/s00702-019-02057-1. Epub 2019 Aug 8.
2
Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa.帕金森病患者接受 Duodopa 治疗后的左旋多巴和 3-OMD 水平。
Eur Neuropsychopharmacol. 2010 Oct;20(10):683-7. doi: 10.1016/j.euroneuro.2010.04.010. Epub 2010 May 31.
3
Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease.长期服用左旋多巴可提高帕金森病患者血浆中左旋多巴的生物利用度。
Neurosci Lett. 2004 Jun 17;363(3):284-7. doi: 10.1016/j.neulet.2004.04.012.
4
Homocysteine levels after acute levodopa intake in patients with Parkinson's disease.帕金森病患者急性摄入左旋多巴后的同型半胱氨酸水平。
Mov Disord. 2009 Jul 15;24(9):1339-43. doi: 10.1002/mds.22607.
5
The pharmacokinetic profile of the "first ever" oral dose of levodopa in de novo patients with Parkinson's disease.帕金森病初发患者首次口服左旋多巴的药代动力学特征。
Clin Neuropharmacol. 2001 Mar-Apr;24(2):95-8. doi: 10.1097/00002826-200103000-00005.
6
Simultaneous determination of L-dopa and 3-O-methyldopa in human platelets and plasma using high-performance liquid chromatography with electrochemical detection.
J Chromatogr B Biomed Sci Appl. 1997 Oct 24;700(1-2):278-82. doi: 10.1016/s0378-4347(97)00307-1.
7
Cysteine decrease following acute Levodopa intake in patients with Parkinson's disease.帕金森病患者急性左旋多巴摄入后半胱氨酸减少。
Neurosci Lett. 2012 Jul 11;521(1):37-9. doi: 10.1016/j.neulet.2012.05.054. Epub 2012 May 26.
8
Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.缓释卡比多巴-左旋多巴(IPX066)用于早期和晚期帕金森病的长期治疗:一项为期9个月的开放标签扩展试验。
CNS Drugs. 2015 Apr;29(4):341-50. doi: 10.1007/s40263-015-0242-2.
9
[Gastrointestinal dysfunction has important implications for plasma L-dopa concentrations in Parkinson's disease].[胃肠功能障碍对帕金森病患者血浆左旋多巴浓度具有重要影响]
Rinsho Shinkeigaku. 2013;53(11):1382-5. doi: 10.5692/clinicalneurol.53.1382.
10
Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's disease.在极晚期帕金森病患者中进行左旋多巴 - 卡比多巴水性分散体的长期十二指肠内输注。
Acta Neurol Scand. 1998 Mar;97(3):175-83. doi: 10.1111/j.1600-0404.1998.tb00633.x.

引用本文的文献

1
Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients.左旋多巴/卡比多巴/恩他卡朋与左旋多巴/卡比多巴/奥匹卡朋一日应用对帕金森病患者的影响。
Cells. 2022 Apr 30;11(9):1511. doi: 10.3390/cells11091511.
2
Wearable Electrochemical Sensors in Parkinson's Disease.可穿戴电化学传感器在帕金森病中的应用。
Sensors (Basel). 2022 Jan 26;22(3):951. doi: 10.3390/s22030951.

本文引用的文献

1
Pill swallowing in Parkinson's disease: A prospective study based on flexible endoscopic evaluation of swallowing.帕金森病患者的吞药问题:一项基于灵活的内镜吞咽评估的前瞻性研究。
Parkinsonism Relat Disord. 2019 May;62:51-56. doi: 10.1016/j.parkreldis.2019.02.002. Epub 2019 Feb 4.
2
Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson's disease.肠道细菌的酪氨酸脱羧酶限制了左旋多巴在帕金森病治疗中的水平。
Nat Commun. 2019 Jan 18;10(1):310. doi: 10.1038/s41467-019-08294-y.
3
Long-term management of Parkinson's disease using levodopa combinations.
左旋多巴联合治疗帕金森病的长期管理。
Expert Opin Pharmacother. 2018 Jun;19(9):1003-1011. doi: 10.1080/14656566.2018.1484108. Epub 2018 Jun 18.
4
Ninety-day Local Tolerability and Toxicity Study of ND0612, a Novel Formulation of Levodopa/Carbidopa, Administered by Subcutaneous Continuous Infusion in Minipigs.新型左旋多巴/卡比多巴制剂ND0612经皮下持续输注给予小型猪的90天局部耐受性和毒性研究。
Toxicol Pathol. 2017 Aug;45(6):764-773. doi: 10.1177/0192623317729891. Epub 2017 Sep 11.
5
Simultaneous determination of levodopa, carbidopa, entacapone, tolcapone, 3-O-methyldopa and dopamine in human plasma by an HPLC-MS/MS method.采用高效液相色谱-串联质谱法同时测定人血浆中的左旋多巴、卡比多巴、恩他卡朋、托卡朋、3-O-甲基多巴和多巴胺。
Bioanalysis. 2015;7(2):207-20. doi: 10.4155/bio.14.230.
6
Binding studies of L-3,4-dihydroxyphenylalanine with human serum albumin.L-3,4-二羟基苯丙氨酸与人血清白蛋白的结合研究。
Mol Biosyst. 2014 Dec;10(12):3101-10. doi: 10.1039/c4mb00408f. Epub 2014 Sep 11.
7
Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications.左旋多巴用于治疗帕金森病的药代动力学考量:聚焦于左旋多巴/卡比多巴/恩他卡朋治疗左旋多巴相关运动并发症
Clin Neuropharmacol. 2013 May-Jun;36(3):84-91. doi: 10.1097/WNF.0b013e31828f3385.
8
Rapid switch from oral antiparkinsonian combination drug therapy to duodenal levodopa infusion.从口服抗帕金森联合药物治疗快速转换为十二指肠左旋多巴输注。
Mov Disord. 2008 Jan;23(1):145-6. doi: 10.1002/mds.21800.
9
Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease.肠内左旋多巴/卡比多巴凝胶输注治疗晚期帕金森病的运动波动和异动症。
Expert Rev Neurother. 2006 Oct;6(10):1403-11. doi: 10.1586/14737175.6.10.1403.
10
Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients.胃排空对帕金森病患者左旋多巴药代动力学的影响。
Clin Neuropharmacol. 2006 Mar-Apr;29(2):61-7. doi: 10.1097/00002826-200603000-00001.